Akèy › Kansè tete negatif triple › Ohio › Columbus
Etid klinik pou Kansè tete negatif triple nan Columbus, OH
16 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Ap rekriteFaz 1
- Ohio State University Comprehensive Cancer Center, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- The Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Local Institution - 0102, Columbus
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Ohio State University, Columbus
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Ohio State University CRS, Columbus
- Ohio Health Research Institute, Columbus
- Anita Stewart Oncology Center, Columbus
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The Ohio State University, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Ohio State University, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
Ap rekrite
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Ap rekriteFaz 2
- Ohio State University Medical Center, Columbus
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
Ap rekrite
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- The Ohio State University, Columbus
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Atlanta, GA20 etid
- Arlington, VA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Tampa, FL15 etid
Lòt etid nan Columbus
- Kansè Poumon ki pa ti selil56 etid
- Kansè nan tete39 etid
- Kansè ovè39 etid
- Kansè (tout kalite)38 etid
- Kansè poumon37 etid
- Leksemi mieloïd egi35 etid
- Lukemi lenfositè kwonik28 etid
- Kansè Metastatik27 etid
- Kansè Endomèt25 etid
- Kansè kolorektal24 etid
- Kansè pwostat24 etid
- Myelom Miltip24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.